Ivry-sur-Seine, France

Alexandre Chenal

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Institut Pasteur. Active years: 2021.


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Alexandre Chenal

Introduction

Alexandre Chenal is a notable inventor based in Ivry-sur-Seine, France. He has made significant contributions to the field of biochemistry, particularly in the development of innovative toxins. His work has implications for various applications in medical research and therapeutic development.

Latest Patents

Chenal holds a patent for the invention titled "Monomeric and functional adenylate cyclase CyaA toxin." This invention discloses a procedure to produce a monomeric and functional form of the CyaA toxin. The innovation allows for the stable maintenance of this functional monodisperse state, even in the absence of any chaotropic agent. This advancement is crucial for further research and potential applications in the medical field.

Career Highlights

Alexandre Chenal is affiliated with the prestigious Institut Pasteur, where he conducts his research. His work at this renowned institution has allowed him to collaborate with leading scientists and contribute to groundbreaking discoveries in the field of microbiology and toxin research.

Collaborations

Chenal has worked alongside talented colleagues, including Audrey Hessel and Véronique Ntsogo Enguene. These collaborations have fostered a productive research environment, leading to significant advancements in their respective fields.

Conclusion

In summary, Alexandre Chenal is an accomplished inventor whose work on the CyaA toxin represents a significant advancement in biochemistry. His contributions at the Institut Pasteur and collaborations with esteemed colleagues highlight his commitment to innovation and research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…